ReviewAdvances in experimental medicine and biology2020
Siglecs at the Host-Pathogen Interface.
Review in Advances in experimental medicine and biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 40 citations in OpenAlex.
- Pathogens of the Human Central Nervous System- the Major Bacterial Pathogens.Molecular neurobiology · 2026Review
- Role of myeloid cells expressing CD169/Siglec-1 in host-pathogen interactions.FEMS microbiology reviews · 2026Review
- Siglec-5 suppresses LPS-induced acute lung injury via negative regulation of HSF1/SYK-mediated ROS production and pyroptosis.Frontiers in medicine · 2026Article
- Decoding sialidase: physiological roles, pathological pathways, and clinical opportunities.Frontiers in cellular and infection microbiology · 2026Review
- Siglec-1 upregulation and macrophage activation in age-related hearing loss: insights from integrated transcriptomic studies in mice and humans.Frontiers in cellular neuroscience · 2026Article
- GlycoRNA, a novel RNA modification.Discover oncology · 2025Review
- The Role of Glycans in Human Immunity-A Sweet Code.Molecules (Basel, Switzerland) · 2025Review
- Molecular Basis of Siglec‑7 Recognition by Neisseria meningitidis Serogroup Y CPS: Implications for Immune Evasion.JACS Au · 2025Article
- Siglec-15 is a putative receptor for porcine epidemic diarrhea virus infection.Cellular and molecular life sciences : CMLS · 2025Article
- Glycosylation editing: an innovative therapeutic opportunity in precision oncology.Molecular and cellular biochemistry · 2025Review
- Exploring CD169Vaccines · 2025Review
- VSTM1/SIRL-1: An Inhibitory Pattern Recognition Receptor Regulating Myeloid Cells.European journal of immunology · 2025Review
- Lectin histochemistry in the small intestines of piglets naturally infected with porcine epidemic diarrhea virus.Journal of veterinary science · 2024Article
- Article
- Infection and the Glycome─New Insights into Host Response.ACS infectious diseases · 2024Review
- Specific interaction between Group BInfection and immunity · 2024Article
- Single-cell sequencing reveals the evolution of immune molecules across multiple vertebrate species.Journal of advanced research · 2024Article
- Membrane linked RNA glycosylation as new trend to envision epi-transcriptome epoch.Cancer gene therapy · 2023Review
- Human sialoglycan ligands for immune inhibitory Siglecs.Molecular aspects of medicine · 2023Review
- The Blessed Union of Glycobiology and Immunology: A Marriage That Worked.Medicines (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Siglecs are sialic acid (Sia) recognizing immunoglobulin-like receptors expressed on the surface of all the major leukocyte lineages in mammals. Siglecs recognize ubiquitous Sia epitopes on various glycoconjugates in the cell glycocalyx and transduce signals to regulate immunological and inflammatory activities of these cells. The subset known as CD33-related Siglecs is principally inhibitory receptors that suppress leukocyte activation, and recent research has shown that a number of bacterial pathogens use Sia mimicry to engage these Siglecs as an immune evasion strategy. Conversely, Siglec-1 is a macrophage phagocytic receptor that engages GBS and other sialylated bacteria to promote effective phagocytosis and antigen presentation for the adaptive immune response, whereas certain viruses and parasites use Siglec-1 to gain entry to immune cells as a proximal step in the infectious process. Siglecs are positioned in crosstalk with other host innate immune sensing pathways to modulate the immune response to infection in complex ways. This chapter summarizes the current understanding of Siglecs at the host-pathogen interface, a field of study expanding in breadth and medical importance, and which provides potential targets for immune-based anti-infective strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.